ReviewCancer letters2012
Increasing the efficacy of tumor cell vaccines by enhancing cross priming.
Review in Cancer letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Universal off-the-shelf TGF-Acta pharmaceutica Sinica. B · 2026Article
- CD8MedComm · 2026Review
- Balancing Immunity: GSK-3's Divergent Roles in Dendritic Cell-Mediated T-Cell Priming and Memory Responses.International journal of molecular sciences · 2025Review
- Glioblastoma vaccines: past, present, and opportunities.EBioMedicine · 2024Review
- Cancer Cell Culture: The Basics and Two-Dimensional Cultures.Methods in molecular biology (Clifton, N.J.) · 2023Article
- DC-Derived Exosomes for Cancer Immunotherapy.Cancers · 2021Review
- Mixed cultures of allogeneic dendritic cells are phenotypically and functionally stable - a potential for primary cell-based "off the shelf" product generation.Central-European journal of immunology · 2021Article
- DC-Based Vaccines for Cancer Immunotherapy.Vaccines · 2020Review
- A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.Cancer immunology, immunotherapy : CII · 2018Article
- Next Generation Cancer Vaccines-Make It Personal!Vaccines · 2018Review
- A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma.Cancer biology & therapy · 2018Article
- Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.Oncotarget · 2018Article
- C-Type Lectin Receptors in Antiviral Immunity and Viral Escape.Frontiers in immunology · 2018Review
- Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.Frontiers in immunology · 2018Review
- Tumor Immuno-Environment in Cancer Progression and Therapy.Advances in experimental medicine and biology · 2017Article
- Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Frontiers in immunology · 2017Review
- TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models.Oncoimmunology · 2016Article
- Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.Oncoimmunology · 2016Article
- Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?Oncoimmunology · 2015Article
- Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer immunotherapy has been attempted for more than a century, and investment has intensified in the last 20 years. The complexity of the immune system is exemplified by the myriad of immunotherapeutic approaches under investigation. While anti-tumor immunity has been achieved experimentally with multiple effector cells and molecules, particular promise is shown for harnessing the CD8 T cell response. Tumor cell-based vaccines have been employed in hundreds of clinical trials to date and offer several advantages over subunit and peptide vaccines. However, tumor cell-based vaccines, often aimed at cross priming tumor-reactive CD8 T cells, have shown modest success in clinical trials. Here we review the mechanisms of cross priming and discuss strategies to increase the efficacy of tumor cell-based vaccines. A synthesis of recent findings on tissue culture conditions, cell death, and dendritic cell activation reveals promising new avenues for clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.